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Abstract
Background: Whereas it is well established that various soluble biomarkers can predict level of liver fibrosis, their ability to
predict liver-related clinical outcomes is less clearly established, in particular among HIV/viral hepatitis co-infected persons.
We investigated plasma hyaluronic acid’s (HA) ability to predict risk of liver-related events (LRE; hepatic coma or liver-related
death) in the EuroSIDA study.
Methods: Patients included were positive for anti-HCV and/or HBsAg with at least one available plasma sample. The earliest
collected plasma sample was tested for HA (normal range 0–75 ng/mL) and levels were associated with risk of LRE. Change
in HA per year of follow-up was estimated after measuring HA levels in latest sample before the LRE for those experiencing
this outcome (cases) and in a random selection of one sixth of the remaining patients (controls).
Results: During a median of 8.2 years of follow-up, 84/1252 (6.7%) patients developed a LRE. Baseline median (IQR) HA in
those without and with a LRE was 31.8 (17.2–62.6) and 221.6 ng/mL (74.9–611.3), respectively (p,0.0001). After adjustment,
HA levels predicted risk of contracting a LRE; incidence rate ratios for HA levels 75–250 or $250 vs. ,75 ng/mL were 5.22
(95% CI 2.86–9.26, p,0.0007) and 28.22 (95% CI 14.95–46.00, p,0.0001), respectively. Median HA levels increased
substantially prior to developing a LRE (107.6 ng/mL, IQR 0.8 to 251.1), but remained stable for controls (1.0 ng/mL, IQR –5.1
to 8.2), (p,0.0001 comparing cases and controls), and greater increases predicted risk of a LRE in adjusted models
(p,0.001).
Conclusions: An elevated level of plasma HA, particularly if the level further increases over time, substantially increases the
risk of contracting LRE over the next five years. HA is an inexpensive, standardized and non-invasive supplement to other
methods aimed at identifying HIV/viral hepatitis co-infected patients at risk of hepatic complications.
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Introduction
The natural history of liver fibrosis progression in patients with
chronic hepatitis B (HBV) or C virus (HCV) infection is highly
variable and depends on both host and viral factors [1].
Individuals co-infected with HIV have accelerated progression of
fibrosis compared to those with hepatitis mono-infection only
[2,3], and hence requires closer monitoring.
Historically, liver biopsy has been considered the gold standard
to diagnose and monitor the progression of fibrosis in patients with
chronic viral hepatitis and other liver diseases. However, liver
biopsy is an invasive procedure, associated with a small risk of
complications and death [4], considerable sampling variability as
well as inter- and intra observer variability in the histological
staging of the biopsy [5]. Outside clinical trials liver biopsy is not
performed in a large proportion of co-infected patients and
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repeated liver biopsies would be unacceptable for most patients
[6,7].
In recent years a high number of serum biomarkers and other
non-invasive methods such as fibroscanning, as markers of liver
fibrosis, have been evaluated. Most of these studies have assessed
associations of these markers with findings from liver biopsy taken
at the same time [8]. Although insightful, this line of investigation
suffers from two major limitations. Firstly, the cross-sectional
design does not allow for studies of temporal changes in biomarker
levels. Secondly, these studies do not inform the evaluation of
whether the markers are able to predict relevant clinical end points
like hepatic decompensation or death. Mehta et al reported that
due to the intrinsic limitations of liver biopsy, the use of this
method as a comparator makes it impossible to distinguish a
perfectly predictive non-invasive marker from a marker with
unacceptable poor predictive potential [9]. Long-term prospective
studies of non-invasive methods evaluated against relevant clinical
end points are hence required to further advance this research
field.
One biomarker, hyaluronic acid (HA) is a component of the
extra cellular matrix and primarily cleared from the bloodstream
by the hepatic sinusoids [10]. Liver disease will therefore reduce
the rate of clearance of HA resulting in elevated plasma levels.
This biomarker is attractive to evaluate as it is easy, reliable,
inexpensive and freely available to measure. Prior studies,
primarily in HCV mono-infected patients, have reported that
HA is an accurate individual marker of fibrosis and predictor of
hepatic complications [11–18]. In HIV, viral hepatitis is a frequent
co-infection, and several HIV-specific factors may affect hepatic
metabolism. Therefore, the aim of this study was to further
evaluate the predictive potential of HA in a large and well
characterized cohort of HIV/viral hepatitis co-infected patients
followed over extended periods of time within the EuroSIDA
study.
Methods
Ethics Statement
Before any study related activities are performed Local Ethical
Committee approval of the study and procedure for obtaining
informed consent from participants is obtained according to local
and/or national regulations in all countries participating in the
study as well as other national regulatory approvals as applicable.
The senior investigator at each clinical site is responsible for
obtaining and maintaining this/these approval(s) at all times
during the conduct of the study.
Patients. The EuroSIDA study is a prospective, observational
cohort of 18,277 HIV-1–infected patients in 108 centers across
Europe, Israel, and Argentina. The study has been described in
detail previously [19]. In brief, patients were enrolled into 9
cohorts from May 1994 onward and median follow-up time is to
December 2011. At recruitment, in addition to demographic and
clinical information, a complete antiretroviral treatment history is
obtained, together with the most recent CD4 cell count and
plasma HIV-RNA measurements. At each follow-up visit, details
on all CD4 cell counts and plasma HIV-RNA values measured
since the last follow-up visit are extracted, as are the dates of
starting and stopping each antiretroviral drug received and the use
of drugs for prophylaxis against opportunistic infections. The dates
of diagnosis of all AIDS-defining illnesses, non–AIDS-defining
malignancies, and other serious infections are also recorded. Anti-
HCV antibody and hepatitis B surface antigen (HBsAg) status was
collected in 1997 for the recruitment of the third cohort, and for
all patients from the first two cohorts who remained under follow-
up at the date. Since 1997 hepatitis serology and virology have
been updated annually.
The EuroSIDA plasma repository was set up in 1997 and
collects plasma samples from all patients at 6 months intervals
when patients are seen for their regular outpatient visits. Samples
are stored at –80uCelsius. Patients with unknown HBsAg or HCV
serostatus and with stored plasma samples were identified in 2006
and anti-HCV IgG and HBsAg in these samples were determined.
Plasma HCV-RNA was quantified in all anti-HCV antibody
positive samples using the Versant HCV-RNA v3.0 assay (Bayer
Diagnostics, Berkeley, CA), which has a lower limit of detection of
615 IU/ml. The epidemiology and clinical outcomes of hepatitis B
and C co-infection in EuroSIDA have been published previously
[20–22].
For the present study all patients positive for anti-HCV
antibodies and/or HBsAg with at least one available plasma
sample were included.
Study end points. The primary end point was the composite
of liver-related death or the development of hepatic encephalop-
athy. To assess the specificity of the predictive potential of HA for
liver related clinical outcomes, non-hepatic deaths as well as new,
non-recurrent AIDS events were included as secondary end
points. Causes of death were determined using the Coding of
Death in HIV (CoDe) algorithm [23]. Hepatic encephalopathy
was defined as grade 3 or 4 based on the West Haven Criteria of
Altered Mental Status In Hepatic Encephalopathy [24]. The
diagnostic criteria are specified in the EuroSIDA list of definitions
of clinical events.
Hyaluronic acid. All quantitative HA measurements were
done centrally using a commercial enzyme linked binding protein
assay (Corgenix, Colorado, USA) with a HA range in a healthy
population between 0–75 ng/mL. The dynamic range of the assay
is from 10 ng/mL to 800 ng/mL (package insert, Corgenix).
Samples with HA concentrations greater than 800 ng/mL were
diluted and re-assayed. The first available centrally stored plasma
sample, after the patient was tested positive for HCV or HBV, was
identified and HA was measured in duplicate according to the
manufacturer’s specifications.
All patients with available samples that developed a liver-related
event during follow-up had HA measured in the last available
sample prior to their event. A control group was selected by
assigning each patient, who did not develop a liver-related event, a
random number in Excel. The list was then sorted according to
the number and every sixth patient was selected as a control. The
technicians, who performed the HA measurements were blinded
to the study outcomes.
Statistical Methods
Patients were divided into two groups. The first group consisted
of patients with either chronic hepatitis B (HBsAg positive;
denoted HBV+) and/or chronic hepatitis C (anti-HCV/HCV-
RNA positive; denoted HCV+) at baseline. The second group
consisted of patients who were HBsAg negative and had
serological evidence of cleared HCV infection (anti-HCV
positive/HCV-RNA negative). Characteristics of patients were
compared between groups using the chi-squared test for propor-
tions or the non-parametric, Wilcoxon or Kruskall-Wallis test for
continuous variables. The incidence of liver related events was
calculated by dividing the number of events by the patient-years of
follow-up (PYFU). Patients were followed from baseline, defined as
the date of the HA measurement, to the clinical event or to last
follow-up for those patients who did not experience a clinical
event. Only one event per patient was included in analyses.
Kaplan-Meier figures were used to estimate the proportion of
Hyaluronic Acid in HIV/Hepatitis Co-Infection
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patients with a liver-related event in different HA strata and
Poisson regression was used to investigate the relationship between
baseline levels of HA and progression to a liver related event.
Potential explanatory factors, in addition to baseline HA, included
age, gender, risk group, ethnic origin, date of recruitment to
EuroSIDA, date of baseline, exposure to antiretrovirals, CD4
count, HIV-viral load, region of Europe, and prior AIDS
diagnosis. Any factor that was significant in univariate analyses
(p,0.1) was included in multivariate analyses.
The change in HA for patients with a liver-related event and the
control group was calculated and standardised for the follow-up
time between the measurements to express the change in HA per
year of follow-up. This measurement was quite variable and
therefore logistic regression was used to describe which factors
were associated with a single standard deviation increase in HA
using the standard deviation of change from all cases and controls.
Similar factors as described above were included as potential
confounding variables.
All analyses were performed using SAS (Statistical Analysis
Software, Cary, NC, USA, Version 9.3).
Results
Baseline Characteristics
Overall 1252 patients were included, and their characteristics at
time of the first HA measurement (i.e. baseline) is shown in table 1.
In total, 1090 (87.1%) were HCV+ (n = 758), HBV+ (n = 256) or
both HBV+ and HCV+ (n = 76), while 162 (12.9%) were anti-
HCV antibody positive/HCV-RNA negative. The median HA
level for all patients was 33.9 ng/mL (interquartile range [IQR]
17.9–69.1), and was higher in patients with chronic HCV infection
(37.7 ng/mL (18.8–76.8)), than in patients with chronic HBV
infection (31.4 ng/mL (18.0–63.4)) or cleared HCV infection
(27.5 ng/mL (15.7–51.1)).
Baseline HA and Risk of a Clinical Progression
During a median follow-up of 8.2 years (IQR 4.7–11.5 years) 84
(6.7%; 52 liver-related death and 32 hepatic encephalopathy)
patients developed a liver-related event (LRE; hepatic encepha-
lopathy or liver-related death). Eight and seven LREs occurred
among patients who were HBsAg positive/anti-HCV negative and
anti-HCV positive/HCV-RNA negative/HBsAg negative, respec-
tively. Among the eight HBV patients, five were on tenofovir
based ART at the date of death. 138 (11.0%) patients died from
non-liver-related causes while 138 (11.0%) developed AIDS during
Table 1. Baseline characteristics of all patients and stratified according to hepatitis status.
All
HBsAg Pos and/or HCV Ab Pos
and HCV RNA pos
HBsAg Neg and HCV Ab pos and
HCV RNA neg p
N % N % N %
All 1252 100 1090 87.1 162 12.9
Gender Male 894 71.4 788 72.3 106 65.4 0.070
Female 358 28.6 302 27.7 56 34.6
Race White 1101 87.9 954 87.5 147 90.7 0.24
Other 151 12.1 136 12.5 15 9.3
Risk MSM 232 18.5 206 18.9 26 16.1 0.24
IDU 756 60.4 648 59.5 108 66.7
Het 153 12.2 134 12.3 19 11.7
Other 111 8.9 102 9.4 9 5.6
Region S 290 23.2 252 23.1 38 23.5 0.95
C 364 29.1 317 29.1 47 29.0
N 276 22.0 238 21.8 38 23.5
E 322 25.7 283 26.0 39 24.1
AIDS Yes 361 28.8 303 27.8 58 35.8 0.036
ARVs None 76 6.1 67 6.2 9 5.6 0.94
Ever ART 121 9.7 106 9.7 15 9.3
Started cART 1055 84.3 917 84.1 138 85.2
Median IQR Median IQR Median IQR
Age Years 38 33–43 38 33–43 38 33–44 0.57
CD4 /mL 452 257–648 453 260–647 442 230–649 0.85
CD4 nadir /mL 136 51–240 139 53–240 105 34–225 0.064
HIV-RNA Log10 copies/ml 1.6 1.6–2.3 1.6 1.5–2.3 1.6 1.6–2.6 0.43
HA date Month/year 8/00 7/98–12/01 8/00 7/98–12/01 3/00 5/98–10/03 0.84
HA ng/mL 33.9 17.9–69.1 35.5 18.2–70.5 27.5 15.7–51.1 0.0054
HBsAg: Hepatitis B surface antigen; HCV Ab: anti-HCV antibody; MSM: men who have sex with men; IDU: intravenous drug use; Het: heterosexual; S/A: south/Argentina;
C: central; N: north; E: east; ARVs: antiretroviral drugs; ART: antiretroviral therapy; cART: combination antiretroviral therapy; HA: hyaluronic acid; IQR: interquartile range.
doi:10.1371/journal.pone.0064283.t001
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follow-up. In unadjusted analysis, the incidence rate for all three
end-points was similar when comparing patients with chronic viral
hepatitis with the ‘‘HCV antibody positive/HCV-RNA negative’’
group (p.0.3 for all comparisons).
For patients who developed an LRE during follow-up the
median HA at baseline was 221.6 ng/mL (IQR 74.9–611.3), while
it was 31.8 ng/mL (IQR 17.2–62.6) for patients who did not
experience an LRE. For patients with chronic viral hepatitis who
developed an LRE (n = 72) the median HA was 229.1 ng/mL
(IQR 78.5–537.3), whereas it was 124.5 ng/mL (74.9–1025.4) for
the seven patients with cleared HCV infection who developed an
LRE (p = 0.72). One of the seven patients had received interferon-
based treatment prior to inclusion in the study. Figure 1 shows the
distribution of baseline HA levels for all patients divided in to
deciles; the proportion of patients experiencing any LRE was low
with low HA. 47 (37.7%) events occurred with a baseline HA
.165.3 ng/mL, while only 6 out of 503 (1.2%) with a baseline HA
,26.7 ng/mL experienced an event.
Patients were then divided into three groups depending on
whether the HA level was below the upper limit of normal
#75 ng/mL), moderately elevated (75–250) or markedly elevated
(.250), and the risk of a LRE was estimated (Figure 2). Those with
normal levels of HA had a cumulative 5-year risk of experiencing
an LRE of 1.0% (95% CI 0.3–1.6%), while the 5 year risk for
moderately elevated HA was 11.6% (6.9–16.2) and for markedly
elevated HA 44.7% (95% CI 32.7–56.7%, p,0.0001). The risk of
contracting a LRE increased gradually and most events occurred
more than 6–12 months after the time when the HA level was
determined (Figure 2).
The prognostic performance of HA to predict LRE, as
estimated by the area under the ROC curve, was 0.83 (95% CI
0.79–0.88) (Figure 3). A HA cut-off value of 100 ng/mL provided
the highest sum of sensitivity (69.03) and specificity (87.0), while
the positive predictive value (PPV) and negative predictive value
(NPV) were 27.6 and 97.5, respectively. Changing the cut-off value
to 250 ng/mL increased the PPV to 46.3, but only decreased the
NPV to 96.1. There were no differences in these performance
estimates when comparing patients with chronic viral hepatitis
with those with cleared HCV infection (results not shown).
The multivariate incidence rates ratios (IRR) for any LRE and
non-liver-related death are shown in figure 4 and 5, respectively.
Age, baseline CD4+ count, HIV viral load and HA level
(categorised as #75, 75–250 and .250 ng/mL) were significant
predictors (p,0.1) of any LRE in the univariate analysis, but HA
was by far the strongest predictor. After adjustment only baseline
HA level, and CD4+ count were significant predictors of LRE,
and HIV-viral load was of marginal significance. Compared to
patients with normal HA levels, those with moderately elevated
HA levels had a 5-fold increase of any LRE (IRR 5.22; 95% CI
2.86–9.26, p = 0.0007), whilst those with markedly elevated HA
level had almost a 30-fold increased incidence of any LRE (IRR
28.22; 95% CI 14.95–46.00, p,0.0001). Sensitivity analyses using
time-updated variables (CD4+ cell count, HIV viral load and time
of cART initiation), adjusting for HCV genotype or censoring
patients at starting any interferon-based therapy (n = 182) did not
change the IRRs significantly (results not shown).
In a sensitivity analysis, excluding patients with HBV infection,
the multivariate IRRs for LRE were similar. With patients with
normal HA levels as reference, the IRR (95% CI) was 8.37 (4.09–
17.12; p,0.0001) and 30.63 (15.14–59.46; p,0.0001) for patients
with HA elevated moderately or markedly, respectively. Only
eight and seven LRE occurred among HBV+ and patients with
resolved HCV infection, respectively, which precluded similar
analyses for the two groups.
For non-liver-related death both age, CD4, HIV viral load and
markedly (but not moderately) elevated HA levels were significant
predictors of this outcome, although the risk for those with
markedly elevated HA levels was modest (IRR 2.17; 95% CI 1.26–
3.76, p = 0.0036) (Figure 5). Conversely, HA levels failed to predict
the occurrence of non-fatal or fatal AIDS events all together
(results not shown).
HA during Follow-up for LRE and Controls
43 (51.2%) patients that developed an LRE during follow-up
had HA measured in their last available sample prior to their event
Figure 1. Distribution of plasma hyaluronic acid levels and any-liver related events during follow-up.
doi:10.1371/journal.pone.0064283.g001
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(cases). 172 (14.7%) other patients without a LRE were included as
random controls. Characteristics of cases included and excluded
from this analysis were comparable, except that included cases had
the first HA measured earlier than the excluded cases (median
dates September 1998 versus March 2000, p = 0.034). Similarly
included controls had an earlier date of HA measurement
compared to excluded controls (median dates September 1999
versus February 2001, p,0.0001). Apart from the difference in
HA when comparing the included cases and included controls
(medians 230.5 ng/mL versus 30.5, p,0.0001), cases were older
(median age 41 versus 37 years, p = 0.0012), had higher HIV RNA
viral load at measurement of HA (medians 2.7 log10 copies/ml
versus 1.6 log10 copies/ml, p,0.0001) and had HA measured
earlier (median date September 1998 versus September 1999,
p = 0.009). The median time between first and last HA measure-
ment was 2.3 years (IQR 1.3–4.0 years) and did not differ when
comparing cases and controls (p = 0.063).
Median change in HA/year was 111.1 ng/mL (IQR 0.8 to
287.5) for the cases compared with 1.0 ng/mL (IQR –5.1 to 8.2)
for the controls (p,0.0001). 12 (28.6%) of the cases had an
increase in HA.210 ng/mL (1 SD increase) compared to 6 of the
controls (3.6%, p,0.0001).
For the patients who developed a LRE the median time from
last HA measurement to the event was 8 months (IQR 4–16).
Those who progressed to an event more quickly after last HA (i.e.
#8 months, 21 patients) had a similar baseline HA (median
270.3 ng/mL, IQR 128.6–701.2) compared to those who
progressed to a liver related event more slowly (ie .8 months,
n = 21, median 227.6 ng/mL, IQR 129.4–380.4, p = 0.55).
However, in those who progressed more quickly, the HA
immediately before the event was higher (median 922.2 ng/mL,
IQR 605.1–1236.5 vs. 402.2 ng/mL, IQR 135.7–627.3,
p = 0.0066), and there was a greater change in HA from first to
last measurement (median change per year 181.3 ng/mL, IQR
104.8–505.3 vs. 7.2 ng/mL, IQR –19.8–115.9, p = 0.0063).
Logistic regression was used to look at odds of .1 SD (210 ng/
mL) increase in HA. In the univariate analysis cases had almost an
11-fold increased odds of .1 SD in HA (odds ratio [OR] 10.87,
95% confidence interval [CI] 3.79–31.19, p,0.0001). In multi-
variate analysis, predictors of .1 SD change in HA were lower
CD4 counts at HA measurement (per doubling) (OR 0.67, 95%
CI 0.51–0.88, p = 0.0042) and being a case (OR 6.77, 95% CI
2.38–19.32, p = 0.0003).
Discussion
Many non-invasive methods for diagnosing liver fibrosis have
been evaluated in recent years, primarily in patients with chronic
HCV infection. With few exceptions, these studies have been
cross-sectional, focusing on staging hepatic fibrosis and lacking
clinical end-points. The Model for End-Stage Liver Disease
(MELD) and the Child-Pugh score are normally used to assess the
prognosis of patients with end-stage liver disease [25,26], but have
not been validated in patients with early stages of liver disease. To
date, the long term prognostic value of fibrosis markers have been
evaluated in only three studies of HCV mono-infected patients
Figure 2. Kaplan Meier progression to any liver-related event according to baseline plasma hyaluronic acid level (ng/mL).
doi:10.1371/journal.pone.0064283.g002
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[15,16,27,28] and in a cohort of both HCV mono-infected and
HIV/HCV co-infected patients [29]. Our study is the first to
evaluate the prognostic value of a biomarker of fibrosis in a large
cohort of viral hepatitis co-infected HIV patients.
The median plasma HA level for all patients was 33.9 ng/mL,
which is comparable to findings from studies of other co-infected
populations [30,31], but lower than in some studies that only
included patients who had a liver biopsy performed [17,32], which
could have selected for patients with more advanced liver fibrosis.
Plasma HA level was a very strong predictor of later development
of hepatic encephalopathy or liver-related death. HA level in the
first available plasma sample after the viral hepatitis diagnosis was
considerably higher in patients who later experienced an LRE
compared to patients that remained free of such an event. The 5-
year risk of developing an LRE was around 45% for patients with
a baseline HA .250 ng/mL, whereas it was 12% in patients with
HA between 75 and 250 ng/mL and only 1% if HA was #75 ng/
mL initially. The optimal cut-off level, as estimated by ROC curve
analysis, was 100 ng/ml, which gave a PPV and NPV of 27.6 and
97.5 for an LRE, respectively. Analyzing patients with HIV/HCV
co-infection separately gave comparable results. Seven patients
with cleared HCV infection (one due to HCV treatment) and no
other known risk factors for liver disease developed an LRE. Their
baseline HA level was lower, but not statistically different, than in
patients with chronic hepatitis who experienced an LRE. This
underscores the importance of also evaluating the extent of liver
fibrosis in this patient group, and closely monitor and explore
other risk factors for liver disease in those with signs of significant
fibrosis.
To evaluate the predictive ability of changes in plasma HA over
time we tested the last available plasma sample in patients who
later developed an LRE and compared them with a control group
Figure 3. Receiver operating characteristic curve for the ability
of plasma hyaluronic acid to predict liver-related events.
doi:10.1371/journal.pone.0064283.g003
Figure 4. Adjusted incidence rate ratios of any liver-related events. Note: The horizontal lines indicate 95% confidence intervals; HA:
hyaluronic acid; HBsAg: hepatitis B surface antigen; HCVab: anti-HCV antibody; Group 1: HBsAg positive and/or anti-HCV/HCV-RNA positive; Group 2:
anti-HCV positive/HCV-RNA negative.
doi:10.1371/journal.pone.0064283.g004
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of random patients who did not develop a LRE. Although not all
patients who developed an LRE or controls had stored samples,
we were able to assess changes in HA in a substantial proportion of
the cases. Patients with an event had an annual increase in median
HA level of around 111 ng/mL compared to 1 ng/mL for the
controls. Of note however, almost one quarter of patients who
developed an event had decreasing HA during follow-up. Serial
measurements will likely reduce the variability and further
improve the prognostic information derived from measuring
HA. Interestingly, we also found that higher CD4 counts were
associated with a reduced risk of substantial increases in HA levels
during follow-up, consistent with the assumed protective role of
high CD4 counts on the risk of progression of liver fibrosis in co-
infected patients [33].
The HA assay is very robust with an average intra- and inter-
assay coefficient of variation around 4% and 6%, respectively
(package insert, Corgenix). Like all other non-invasive fibrosis
markers, HA is not liver specific. Increased HA levels can also be
seen during synovial inflammation and cartilage destruction in
rheumatoid arthritis and other connective tissue diseases, due to
increased production and passage of HA into the circulation [34].
HA may increase after intake of food, most likely due to an
increase in post-prandial intestinal and thoracic duct lymph-flow
with increased input of HA in to the circulation [35,36]. The
patients in EuroSIDA are not required to be fasting before blood
samples are drawn. Thus, it is possible that the low positive
predictive value we observed, but also decreases in HA during
follow-up in around a quarter of all patients who developed an
LRE, to some extent could be due to the influence of food intake.
HA is not measured routinely in most biochemistry laboratories,
and before introducing HA as a routine test in clinical practice,
further studies with clinical end-points validating HA against liver-
biopsy and other non-invasive methods, including biomarkers that
use routine laboratory tests, are required. Future studies should
also define the optimal cut off values to maximise the predictive
value of HA in routine clinical settings and also investigate factors
influencing the longitudinal dynamics of HA. However, the
present study indicates that HA could be a useful biomarker to
estimate the long-term risk of liver disease. Patients with low
(,75 ng/mL) and stable plasma HA levels would have very little
risk of clinical progression over the next five years. Patients with
elevated or increasing plasma HA levels should be followed
clinically more closely and their risk of liver disease should be
assessed with more specific tests.
Our findings also have implications for future research efforts
focused on assessing the impact of impairment of liver function on
various types of clinical outcomes in HIV positive populations. For
example, impairment of liver function may contribute to
dysregulation of coagulation in HIV positive persons [37] which
is associated with mortality [38]. To pursue these research
questions, it has proven to be a challenge to reliably evaluate
the degree of liver impairment in large cohorts of patients followed
in multiple sites, as liver biopsy is infrequently performed, and
Fibroscan is only available in selected sites. Additionally, the
interpretation of other non-invasive measures of fibrosis such as
APRI and FIB-4 is complicated by the fact that some of the
parameters used in these scores are affected by HIV-specific
factors [39,40]. Comparative studies in co-infected patients have
Figure 5. Adjusted incidence rate ratios of any non-liver-related events. Note: The horizontal lines indicate 95% confidence intervals; HA:
hyaluronic acid; HBsAg: hepatitis B surface antigen; HCVab: anti-HCV antibody; Group 1: HBsAg positive and/or anti-HCV/HCV-RNA positive; Group 2:
anti-HCV positive/HCV-RNA negative.
doi:10.1371/journal.pone.0064283.g005
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shown HA to be superior to APRI and FIB-4 in diagnosing
advanced fibrosis [14,17,18]. Hence, soluble biomarkers that
assess impaired liver function via other mechanisms are attractive
research tools. Our findings support that HA is a suitable
candidate for this purpose. Indeed, our data was part of the
reason why the INSIGHT (International Network for Strategic
Initiatives in Global HIV Trials) network chose HA as the most
suitable marker of liver fibrosis [31,41].
This study has some limitations. Until 2010, hepatic enceph-
alopathy and liver-related deaths was the only manifestations of
decompensated liver cirrhosis that is routinely collected in
EuroSIDA, and it is likely therefore that the study underestimates
the burden of other types of non-fatal end-stage liver disease
events. It is possible that the positive predictive value of HA would
have increased had ascertainment of such events also been
available. Only 43 out 84 patients with an LRE had a follow-up
sample available. It is likely that those who died most quickly had
no follow-up sample, thus leading us to underestimate the rate of
change in HA. Also, we were not able to compare HA with MELD
or other biomarkers of fibrosis like APRI and FIB-4, since INR
and platelet levels have only been collected routinely in EuroSIDA
since 2006. Likewise, we did not have access to information on
alcohol consumption or liver biopsy results from the fraction of
patients who had this procedure performed.
In summary, this large cohort study demonstrates that baseline
HA was a strong predictor of later development hepatic
encephalopathy or liver-related death in HIV-1 patients co-
infected with HBV and/or HCV. Patients, who during follow-up
experienced a liver-related event, had higher annual increase in
HA compared to patients without an event, while a high CD4 cell
count was associated with a less rapid increase in HA. Therefore,
plasma HA may be useful, either alone or in combination with
other non-invasive methods, to monitor progression of liver disease
and risk of complications in patients with chronic viral hepatitis.
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